Canertinib dihydrochloride
|
|
|
- CAS-Nr.
- 289499-45-2
- Englisch Name:
- Canertinib dihydrochloride
- Synonyma:
- CI103;CI 103;CI-1033;Canertinib HCl;Canertinib 2HC;Canertinib.2HCL;CI1033 dihydrochloride;CI 1033 dihydrochloride;CI-1033 dihydrochloride;PD-183805 dihydrochloride
- CBNumber:
- CB11011729
- Summenformel:
- C24H27Cl3FN5O3
- Molgewicht:
- 558.86
- MOL-Datei:
- 289499-45-2.mol
|
Canertinib dihydrochloride Eigenschaften
- storage temp.
- Sealed in dry,Store in freezer, under -20°C
- Löslichkeit
- DMSO: >10mg/mL
- Aggregatzustand
- solid
Canertinib dihydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
The HER family of receptor tyrosine kinases, EGFR, HER2, HER3, and HER4, mediate proliferation, migration, adhesion, differentiation, and survival in many different cell types and have been implicated in the development and progression of a variety of human tumors.Canertinib dihydrochloride is an irreversible quinazoline-based HER family tyrosine kinase inhibitor with IC50 values of 0.8, 19, and 7 nM for blocking in vitro activity of EGFR, HER2, and HER4, respectively. As a broadly applicable anti-cancer agent, it has been used to suppress proliferation of malignant peripheral nerve sheath tumor cells (effective concentration of 250-500 nM), to inhibit growth and induce dose-dependent apoptosis in a panel of neuroblastoma cell lines (IC50s = 0.94-2.45 μM), and to reduce proliferation of acute myeloid leukemia cells (IC50 = 0.27 μM). Canertinib dihydrochloride also displays anti-neoplastic activity towards T98G glioblastoma cells, HCT8 colorectal carcinoma cells, and cells expressing the breast cancer resistance protein.
Canertinib dihydrochloride Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Canertinib dihydrochloride Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 153)Lieferanten
289499-45-2()Verwandte Suche:
- CANERTINIB DIHYDROCHLORIDE
- N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride
- Canertinib.2HCL
- CI-1033
- N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride
- N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride
- Canertinib HCl
- CI 103
- CI103
- PD-183805 dihydrochloride
- Canertinib dihydrochloride/Canertinib
- CI 1033 dihydrochloride
- CI1033 dihydrochloride
- CI-1033 dihydrochloride
- Canertinib dihydrochloride N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride
- N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide dihydr
- Canertinib (hydrochloride)
- Canertinib Dihydrochloride (CI-1033 HCl)
- Canertinib (CI-1033) HCl
- CANERTINIB;CI-1033 DIHYDROCHLORIDE;PD-183805 DIHYDROCHLORIDE;CI1033 DIHYDROCHLORIDE;CI 1033 DIHYDROCHLORIDE;PD183805 DIHYDROCHLORIDE;PD 183805 DIHYDROCHLORIDE
- Canertinib dihydrochloride (CI-1033
- Canertinib (CI-1033) 2HCl
- Canertinib (CI-1033) dihydrochloride
- Canertinib 2HC
- Canertinib dihydrochloride USP/EP/BP
- 289499-45-2
- C24H27Cl3FN5O3
- C24H25ClFN5O32HCl
- Inhibitors
- API
